FindMyRecallSubscribe
Class II: temporary or reversible health riskTerminated

Teva Pharmaceuticals Dextroamphetamine Saccharate Recall

Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amph…

Teva Pharmaceuticals USA Inc · Parsippany, NJ

Risk level
Class II
Reported by FDA
Sep 21, 2022
Recall ID
D-1539-2022
Check your lot numberHow we source this data

Summary

Teva Pharmaceuticals recalled Dextroamphetamine Saccharate starting Aug 29, 2022. The FDA classified it as Class II (temporary or reversible health risk) and published enforcement report D-1539-2022 on Sep 21, 2022. Reason: Labeling: Label Error on Declared Strength; A sealed 100-count bottle labeled with 15 mg actually contained 100 tablets of 20 mg strength of the drug product. Status: Terminated.

Why it was recalled

Labeling: Label Error on Declared Strength; A sealed 100-count bottle labeled with 15 mg actually contained 100 tablets of 20 mg strength of the drug product.

Product description

Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets (Mixed Salts of a Single Entity Amphetamine Product), 15 mg, Rx Only, 100 tablets per bottle, Teva Pharmaceuticals USA, Inc. North Wales, PA 19454, NDC 0555-0777-02.

Lot numbers, UPCs & expiration codes

Lot #: 100023340, Exp 10/2024

Where it was sold

Nationwide in the US.

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-1539-2022
Classification
Class II
Status
Terminated
Recall initiated
Aug 29, 2022
FDA report date
Sep 21, 2022
Quantity
83,703 bottles
Recall type
Voluntary: Firm initiated
Recalling firm
Teva Pharmaceuticals USA Inc

Original FDA data

Every field from FDA enforcement report D-1539-2022, exactly as published.

Show all FDA fields
City
Parsippany
State
NJ
Status
Terminated
Country
United States
Event ID
90803
Address
400 Interpace Pkwy Bldg A
Code information
Lot #: 100023340, Exp 10/2024
Postal code
07054-1120
Report date
Sep 21, 2022
Product type
Drugs
Recall number
D-1539-2022
Classification
Class II
Recalling firm
Teva Pharmaceuticals USA Inc
Product quantity
83,703 bottles
Termination date
Aug 14, 2023
Reason for recall
Labeling: Label Error on Declared Strength; A sealed 100-count bottle labeled with 15 mg actually contained 100 tablets of 20 mg strength of the drug product.
Voluntary / mandated
Voluntary: Firm initiated
Product description
Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets (Mixed Salts of a Single Entity Amphetamine Product), 15 mg, Rx Only, 100 tablets per bottle, Teva Pharmaceuticals USA, Inc. North Wales, PA 19454, NDC 0555-0777-02.
Distribution pattern
Nationwide in the US.
Recall initiation date
Aug 29, 2022
Initial firm notification
Letter
Center classification date
Sep 16, 2022

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-1539-2022, published Sep 21, 2022. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls